HBV Mutation Detail Information

> N236T Search Result


Mutation Information
Mutation Site N236T
Mutation Type Amino acid level
Gene/Protein/Region Type RT
Relevant Drug lamivudine (LAM);adefovir (ADV);tenofovir (TDF)
Literature Information
PubMed PMID 21871497
Published Year 2011
Journal Antiviral research
Title The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Author Billioud G,Pichoud C,Puerstinger G,Neyts J,Zoulim F
Evidence HepG2 stable cell line permanently expressing wild type (WT) HBV or the main HBV mutants resistant to lamivudine and/or adefovir (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I, rtL180M+rtM204I, rtN236T, rtA181V, rtA181V+rtN236T, rtA181T, rtA181T+rtN236T) were treated with AT-61, AT-130 or BAY-41 4109.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation